Annovis Bio Inc. (NYSE: ANVS) has achieved a significant milestone in its Alzheimer's disease drug development program. The company announced that it received clearance from the U.S. Food and Drug Administration (FDA) to proceed with Phase 3 clinical trials for its lead compound, buntanetap, following an End-of-Phase 2 meeting held on October 10, 2024. This decision paves the way for Annovis to investigate buntanetap's potential as both a short-term symptomatic treatment and a long-term disease-modifying therapy for patients with early-stage Alzheimer's disease.
The Phase 3 program will consist of two clinical trials. The first is a 6-month study designed to confirm buntanetap's symptomatic effects in patients with early-stage Alzheimer's disease. The second is an 18-month study aimed at evaluating its potential as a disease-modifying treatment. Annovis Bio is targeting a potential New Drug Application (NDA) submission within one year of the 6-month study's initiation, contingent on positive results.
Safety Profile and Formulation
The FDA has not raised any safety concerns regarding buntanetap, including data related to liver enzymes, drug interactions, dose selection, pharmacokinetics, and population pharmacokinetics. The agency also confirmed that development can proceed using the new crystal form of buntanetap.
Management Commentary
"We are now ready to move into the highly anticipated Phase 3 stage," said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio. "Our priority is to bring the treatment to patients as early as possible, and we are committed to ensuring the next clinical trial is executed at the highest standards to attain an expedited NDA submission. Our team is already preparing for trial initiation early next year and will continue to keep you updated as we advance towards our goal."
About Annovis Bio
Annovis Bio Inc. is a clinical-stage drug platform company focused on developing therapies for neurodegenerative disorders, including Alzheimer's and Parkinson's diseases. The company's approach targets multiple neurotoxic proteins with the goal of restoring brain function and improving the quality of life for patients.
